Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) and RYTHM (NASDAQ:RYM – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Institutional and Insider Ownership
89.1% of Jazz Pharmaceuticals shares are held by institutional investors. Comparatively, 6.0% of RYTHM shares are held by institutional investors. 4.1% of Jazz Pharmaceuticals shares are held by company insiders. Comparatively, 3.5% of RYTHM shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Jazz Pharmaceuticals and RYTHM”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jazz Pharmaceuticals | $4.27 billion | 3.77 | -$356.15 million | $14.50 | 17.07 |
| RYTHM | $17.28 million | 3.16 | -$33.26 million | ($10.53) | -2.38 |
RYTHM has lower revenue, but higher earnings than Jazz Pharmaceuticals. RYTHM is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and target prices for Jazz Pharmaceuticals and RYTHM, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jazz Pharmaceuticals | 0 | 1 | 16 | 1 | 3.00 |
| RYTHM | 1 | 0 | 0 | 0 | 1.00 |
Jazz Pharmaceuticals currently has a consensus target price of $285.44, suggesting a potential upside of 15.30%. Given Jazz Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Jazz Pharmaceuticals is more favorable than RYTHM.
Profitability
This table compares Jazz Pharmaceuticals and RYTHM’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jazz Pharmaceuticals | 20.45% | 33.97% | 13.02% |
| RYTHM | -6.20% | -12.57% | -2.60% |
Volatility & Risk
Jazz Pharmaceuticals has a beta of 0.36, indicating that its stock price is 64% less volatile than the S&P 500. Comparatively, RYTHM has a beta of 9.44, indicating that its stock price is 844% more volatile than the S&P 500.
Summary
Jazz Pharmaceuticals beats RYTHM on 13 of the 15 factors compared between the two stocks.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson’s disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
About RYTHM
Agrify Corporation develops precision hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. The company offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. It also provides associated services comprising consulting, engineering, and construction. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Billerica, Massachusetts.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
